NICE rejects Novartis' Glivec for GIST use; Pfizer, Sanofi release first pharma iPad apps;

  @FiercePharma: E.U. trade group to sharply limit free samples. Article | Follow @FiercePharma

> The Novartis drug Glivec got the thumbs-down from Britain's cost-effectiveness watchdog as a treatment for patients who have had a gastrointestinal stromal tumor removed by surgery. Report

> The first big pharma apps specially designed for Apple's iPad have started to emerge, with Pfizer and Sanofi leading the charge with upgrades to their existing iPhone apps. Report

> A once-weekly diabetes drug being developed by Eli Lilly and Amylin Pharmaceuticals was slightly better at controlling blood sugar than Sanofi-Aventis' Lantus, but led to weight loss instead of gain, according to data from a study. Report

> Lupin, an Indian generics maker, is looking for acquisitions in Brazil and Mexico to expand its revenue from the Latin American region. Report

> To those who believe we have everything we need in the lipid-lowering world, Ben Stakely, Kowa Pharmaceuticals America CEO and president, has one thing to say: "I would argue with you." Report

> Mylan got the FDA nod for a generic version of Pfizer's drug Procardia XL, which is approved to treat angina and high blood pressure. Report

> Watson Pharmaceuticals won marketing approval for a generic version of Cephalon's drug Fentora, which is used to treat extreme pain in cancer patients. Report

Biotech News

@FierceBiotech: On its 10th birthday, the importance of sequencing is still debated. Article | Follow @FierceBiotech    

@JohnCFierce: Venter on sequencing: "I think it's far more important than walking on the Moon; not much has happened since walking on the Moon." | @JohnCFierce 

> EMA recommends Merck heart drug. News

> Analysts fret over Pfizer's litany of pipeline snafus. Item

> UMB plots $675M biotech park expansion. Story

> FDA delays decision on AZ's motavizumab. Report

> Gilead to buy CGI Pharm for $120M. Article

> Sanofi inks $375M deal with Metabolex for diabetes target. Story

And finally ... For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a new study. Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…